Targeted relief for life-saving medicine

Of all the customs measures in the Federal Budget 2026-27, this one matters most for public health: cancer-related active pharmaceutical ingredients (APIs) have been exempted from customs duty. APIs are the raw chemical compounds that make a medicine work. For oncology drugs they are often imported and make up most of the manufacturing cost. Taking the import duty off these inputs is meant to lower the landed cost of cancer treatment and ease the burden on patients and the health system.

Why APIs matter to drug pricing

A finished oncology medicine is built on its API. When that ingredient crosses the border carrying customs duty, additional customs duty and other charges, every rupee of tax goes into the manufacturer's cost and, in the end, into the shelf price. By exempting cancer APIs, the government is going after the most expensive part of the supply chain instead of offering a broad, loosely aimed discount.

What the exemption covers

Scope: active pharmaceutical ingredients specifically used in cancer treatment, identified by tariff classification.
Relief: exemption from customs duty on import.
Goal: reduce the cost of locally manufactured oncology drugs and improve affordability.
Effective date: 1 July 2026, in line with the wider National Tariff Policy 2025-30 tariff rationalisation.

A worked example

Suppose a pharmaceutical manufacturer imports a cancer API consignment with a customs value of Rs 10,000,000. If that line previously attracted, say, a combined customs duty of 5%, the duty alone would have been Rs 500,000 added to cost. With the exemption, that Rs 500,000 is removed from the cost stack. Over a full year of imports, that adds up to a real cut in the cost of goods.

Where this sits in the bigger picture

The cancer-API exemption is part of a broader tariff overhaul. Budget 2026-27 cuts customs duty on hundreds of input lines, trims additional customs duty across thousands of lines and reduces regulatory duty on selected items. Sitting alongside it are exemptions for agricultural machinery and defence imports, plus a reduced duty for the construction-vehicle category. The cancer relief is the health side of the same policy: lower input costs should mean lower prices for patients.

Compliance still matters

An exemption does not mean less paperwork. Importers must still classify goods under the correct tariff heading, hold the right import paperwork and reconcile their landed-cost ledgers accurately. For pharmaceutical companies, that means finance teams must update standard costs, reprice products where appropriate and keep audit-ready records.

Zaffre Axon can help here. Zaffre Tech's platform, which includes the Zaffre HRM module for people and payroll, keeps finance, invoicing and statutory settings in one place, so duty, sales tax and withholding rules are applied the same way every time. When a customs change like the cancer-API exemption comes in, finance teams can update cost assumptions once in Zaffre Axon and keep the books compliant across every department.

Bottom line

The cancer-API customs exemption is a narrow, well-aimed measure. It takes duty off the most expensive input in oncology manufacturing, with the aim of making cancer medicine cheaper and easier to get. Importers should update their costings, get their tariff classification right and let their finance system handle the routine compliance work.

References: Finance Act 2026 (Federal Budget 2026-27); Customs Act 1969; National Tariff Policy 2025-30; FBR.

Book a demo of Zaffre Axon to see how Zaffre Tech keeps your import costing, invoicing and tax settings compliant after each budget change.

Cancer Treatment APIs Exempted from Customs Duty in Budget 2026-27